IP Library Granted Patent US 12,599,548
Granted Patent B2
US 12,599,548 · App. 18/732,895 · Granted Apr 14, 2026

Method of treating oxidative stress in skin and compositions therefor

Inventors: Tomohiro Hakozaki (Cincinnati, OH); Leo Timothy Laughlin, II (Mason, OH); Matthew Clair Ehrman (Singapore, SG); XiPing Ng (Singapore, SG)
Assignee: The Procter & Gamble Company
A61K8/604A61K8/342A61K8/365A61K8/675A61Q19/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,599,548
App. No.
18/732,895
Granted
Apr 14, 2026
Kind
B2
Abstract

Cellular energy levels in skin cells affected by oxidative stress can be improved through the use of a skin care composition that includes a sucrose ester and a fatty alcohol present at a specific ratio. The fatty alcohol and sucrose ester, when incorporated into a skin care composition at a specific ratio, can provide a synergistic improvement in cellular ATP level for skin cells suffering from the effects of oxidative stress.

Claims (17)

1 . A skin care composition, comprising:

a) a sucrose ester chosen from sucrose laurate, sucrose dilaurate, sucrose trilaurate, or mixtures thereof;

b) hexyldecanol; and

c) a dermatologically acceptable carrier, wherein the fatty alcohol and sucrose ester are present at a weight ratio of 1:1 to 5:1, based on the weight of the composition, and the combination of sucrose ester and fatty alcohol has a synergy factor of at least 1.1 according to the Oxidative Stress Test.

2 . The skin care composition of claim 1 , wherein the sucrose ester comprises a mixture of sucrose laurate and sucrose dilaurate.

3 . The skin care composition of claim 2 , wherein sucrose laurate is present at about 55% to about 80%, by weight of the sucrose ester and the sucrose dilaurate is present at about 20% to about 45% by weight of the sucrose ester.

4 . The skin care composition of claim 1 , wherein the composition further comprises at least one additional ingredient chosen from vitamins, minerals, peptides, sugar amines, sunscreen agents, oil control agents, flavonoid compounds, anti-oxidants, preservatives, protease inhibitors, tyrosinase inhibitors, anti-inflammatory agents, moisturizing agents, exfoliating agents, skin lightening agents, lubricants, anti-acne actives, chelating agents, anti-wrinkle actives, anti-atrophy actives, phytosterols, N-acyl amino acid compounds, antimicrobials, and antifungals, conditioning agents, emulsifiers, rheology modifiers, or mixtures thereof.

5 . The skin care composition of claim 4 , wherein the additional ingredient is a skin care active chosen from vitamin B3 compounds, undecylenoyl phenylalanine, vitamin E compounds, palmitoylated dipeptides, palmitoylated pentapeptides, vitamin A compounds, or mixtures thereof.

6 . The skin care composition of claim 4 , wherein the composition further comprises a rheology modifier chosen from the group consisting of acrylates/C10-30 alkyl acrylate crosspolymer, acrylates vinyl isodeconate crosspolymers, polyacrylate crosspolymer-6, sodium polyacryloyldimethyl taurate, or mixtures thereof.

7 . The skin care composition of claim 4 , wherein the composition further comprises an emulsifier chosen from glycereth-25 pyrrolidonecarboxylic acid isostearate, PEG-100 stearate, steareth-2, steareth-21, or mixtures thereof.

8 . A method of improving cellular energy levels in skin cells affected by oxidative stress, comprising:

a) identifying a target portion of skin where treatment is desired; and

b) applying the skin care composition of claim 1 .

9 . The method of claim 8 , wherein the sucrose ester and the fatty alcohol are each present at about 0.0001% to about 10%, by weight of the composition.

10 . The method of claim 8 , wherein the fatty alcohol is present at about 0.0001% to about 10%, by weight of the composition.

11 . The method of claim 8 , wherein the target portion of skin exhibits a sign of oxidative stress and the composition is applied over the course of a treatment period.

12 . The method of claim 11 , wherein the treatment period is at least 4 weeks and the composition is applied at least once per day.

Continuity (3)
Continuation 17549980 · Dec 14, 2021
Provisional Application 63125011 · Dec 14, 2020
Related Publication 20240315946A1 · Sep 26, 2024
References Cited (135)
US 3755560A · Dickert et al. · 1973 [cited by applicant]
US 4421769A · Dixon et al. · 1983 [cited by applicant]
US 5011681A · Ciotti et al. · 1991 [cited by applicant]
US 5766575A · Crotty et al. · 1998 [cited by applicant]
US 5830499A · Bouwstra · 1998 [cited by applicant]
US 5872112A · Blank · 1999 [cited by applicant]
US 5939082A · Oblong et al. · 1999 [cited by applicant]
US 5972359A · Sine et al. · 1999 [cited by applicant]
US 6013270A · Hargraves · 2000 [cited by applicant]
US 6174533B1 · Sanogueira, Jr. et al. · 2001 [cited by applicant]
US 6238678B1 · Oblong et al. · 2001 [cited by applicant]
US H2013H · Boyd et al. · 2002 [cited by applicant]
US 6492326B1 · Robinson · 2002 [cited by applicant]
US 6524598B2 · Sunkel et al. · 2003 [cited by applicant]
US 6696049B2 · Vatter · 2004 [cited by applicant]
US 7737103B2 · Hloucha · 2010 [cited by applicant]
US 7754775B2 · Mercier et al. · 2010 [cited by applicant]
US 9221986B2 · Sujeeth · 2015 [cited by examiner]
US 9446265B2 · Jansen et al. · 2016 [cited by applicant]
US 9498420B2 · Laughlin, II · 2016 [cited by applicant]
US 9757317B2 · Laughlin, II et al. · 2017 [cited by applicant]
US 9795552B2 · Tanner et al. · 2017 [cited by applicant]
US 9833398B2 · Hakozaki et al. · 2017 [cited by applicant]
US 9949917B2 · Moussou et al. · 2018 [cited by applicant]
US 10512603B2 · Almiñana Domènech et al. · 2019 [cited by applicant]
US 10660838B2 · Hakozaki et al. · 2020 [cited by applicant]
US 10874600B2 · Hakozaki et al. · 2020 [cited by applicant]
US 11571379B2 · Hakozaki et al. · 2023 [cited by applicant]
US 11968993B2 · Schoeppe · 2024 [cited by applicant]
US 20020022040A1 · Robinson et al. · 2002 [cited by applicant]
US 20030049212A1 · Robinson et al. · 2003 [cited by applicant]
US 20040175347A1 · Bissett · 2004 [cited by applicant]
US 20040265258A1 · Robinson et al. · 2004 [cited by applicant]
US 20050220726A1 · Pauly et al. · 2005 [cited by applicant]
US 20050238677A1 · Mercier · 2005 [cited by applicant]
US 20060165735A1 · Abril et al. · 2006 [cited by applicant]
US 20060275237A1 · Bissett · 2006 [cited by applicant]
US 20070196344A1 · Osborne et al. · 2007 [cited by applicant]
US 20080181956A1 · Ha et al. · 2008 [cited by applicant]
US 20080206373A1 · Millikin et al. · 2008 [cited by applicant]
US 20100004729A1 · Chew et al. · 2010 [cited by applicant]
US 20100047296A1 · Banowski et al. · 2010 [cited by applicant]
US 20100092408A1 · Breyfogle et al. · 2010 [cited by applicant]
US 20100189669A1 · Hakozaki · 2010 [cited by applicant]
US 20100239510A1 · Ha et al. · 2010 [cited by applicant]
US 20100272667A1 · Kyte, III et al. · 2010 [cited by applicant]
US 20110097286A1 · Swanson · 2011 [cited by applicant]
US 20110262025A1 · Jarrold et al. · 2011 [cited by applicant]
US 20120128603A1 · Tanaka · 2012 [cited by applicant]
US 20120128683A1 · Shantha · 2012 [cited by applicant]
US 20120148510A1 · Hakozaki et al. · 2012 [cited by applicant]
US 20120148515A1 · Hakozaki et al. · 2012 [cited by applicant]
US 20120156146A1 · Hakozaki et al. · 2012 [cited by applicant]
US 20120197016A1 · Laughlin, II et al. · 2012 [cited by applicant]
US 20130022557A1 · Swanson et al. · 2013 [cited by applicant]
US 20140271506A1 · Laughlin, II et al. · 2014 [cited by applicant]
US 20140328775A1 · Laughlin, II et al. · 2014 [cited by applicant]
US 20150196464A1 · Jansen et al. · 2015 [cited by applicant]
US 20160128924A1 · Lee et al. · 2016 [cited by applicant]
US 20170348221A1 · Maruyama · 2017 [cited by applicant]
US 20170348551A1 · Doering et al. · 2017 [cited by applicant]
US 20180221256A1 · Sunkel · 2018 [cited by applicant]
US 20180280282A1 · Mcconaughy et al. · 2018 [cited by applicant]
US 20190380945A1 · Hakozaki et al. · 2019 [cited by applicant]
US 20200009123A1 · Hakozaki et al. · 2020 [cited by applicant]
US 20200178881A1 · Purwar et al. · 2020 [cited by applicant]
US 20200253851A1 · Hakozaki et al. · 2020 [cited by applicant]
US 20200405614A1 · Hakozaki · 2020 [cited by applicant]
US 20200405621A1 · Hakozaki · 2020 [cited by applicant]
US 20200405622A1 · Paufique · 2020 [cited by applicant]
US 20210228469A1 · Hakozaki et al. · 2021 [cited by applicant]
US 20220062155A1 · Billinger · 2022 [cited by applicant]
US 20220183936A1 · Ehrman et al. · 2022 [cited by applicant]
US 20220183948A1 · Hakozaki et al. · 2022 [cited by applicant]
CN 103655313A · 2014 [cited by applicant]
CN 104027265A · 2014 [cited by applicant]
CN 105456176A · 2016 [cited by applicant]
CN 105560158A · 2016 [cited by applicant]
CN 105662908A · 2016 [cited by applicant]
CN 107308018A · 2017 [cited by applicant]
CN 107595756A · 2018 [cited by applicant]
CN 108379165A · 2018 [cited by applicant]
CN 109620770A · 2019 [cited by applicant]
CN 110101649A · 2019 [cited by applicant]
CN 110314109A · 2019 [cited by applicant]
CN 110547985A · 2019 [cited by applicant]
EP 1216625A1 · 2002 [cited by applicant]
EP 1842530A1 · 2007 [cited by applicant]
JP 2000061289A · 2000 [cited by applicant]
JP 2001031993A · 2001 [cited by applicant]
JP 2002080370A · 2002 [cited by applicant]
JP 2004154060A · 2004 [cited by applicant]
JP 2005179237A · 2005 [cited by applicant]
JP 2009209146A · 2009 [cited by applicant]
JP 2014101378A · 2014 [cited by applicant]
JP 2016030728A · 2016 [cited by applicant]
JP 2017014135A · 2017 [cited by applicant]
JP 2017061433A · 2017 [cited by applicant]
JP 2017081848A · 2017 [cited by applicant]
JP 2018039770A · 2018 [cited by applicant]
JP 2018118931A · 2018 [cited by applicant]
JP 2019014709A · 2019 [cited by applicant]
JP 2019019077A · 2019 [cited by applicant]
JP 2019085365A · 2019 [cited by applicant]
JP 2020097549A · 2020 [cited by applicant]
WO 9947141A1 · 1999 [cited by applicant]
WO 2006040048A1 · 2006 [cited by applicant]
WO 2007105706A1 · 2007 [cited by applicant]
WO 2011074143A1 · 2011 [cited by applicant]
WO 2012068357A2 · 2012 [cited by applicant]
WO 2013049580A2 · 2013 [cited by applicant]
WO 2018114742A1 · 2018 [cited by applicant]
WO 2022132689A1 · 2022 [cited by applicant]
Boulier, V. et al. “New formulations containing a blend of sucrose laurates”, Research Disclosure database No. 535032, Nov. 20008. [cited by examiner]
“Sensitive Multi-Benefit Integral Care for Sensitive Skin”, Mintel, Retrieved from URL Link: Http://www.gndp.com, Published on Feb. 2016, 7 pgs. [cited by applicant]
15943M PCT Search Report and Written Opinion for PCT/US2021/063194 dated Apr. 8, 2022, 20 pages. [cited by applicant]
All Office Actions; U.S. Appl. No. 17/549,980, filed Dec. 14, 2021. [cited by applicant]
All Office Actions; U.S. Appl. No. 17/155,151, filed Jan. 22, 2021. [cited by applicant]
All Office Actions; U.S. Appl. No. 17/549,989, filed Dec. 14, 2021. [cited by applicant]
All Office Actions; U.S. Appl. No. 18/074,577, filed Dec. 5, 2022. [cited by applicant]
Boulier et al., “New Formulations containing a blend of Sucrose Laurates”, Sensient Cosmetic Technology, vol. 535, Nov. 1, 2008, 4 pages. [cited by applicant]
CHIfiger anti aging moisturizing and beauty, URL Link—http;//www.cosdna.com/chs/, dated Oct. 24, 2019, pp. 1-10. [cited by applicant]
Clear Lotion, ID 7622851, Mintel GNPD[online], May 2020, URL Link-, https://www.portal.mintel.com, dated Jul. 20, 2023, 5 pgs. [cited by applicant]
Cruces et al. “Improved Synthesis of Sucrose Fatty Acid Monoesters JAOCS”, vol. 78, No. 5(2001) pp. 541-546. (Year: 2001). [cited by applicant]
Ice Eye Gel, ID 6159177, Mintel GNPD[online],Dec. 2018, URL, https://www.portal.mintel.com, Dated Jul. 20, 2023, 4 pgs. [cited by applicant]
Ixing, Revitalizing Skin Firming and Refining Emulsion, Liquid SPF 15, URL Linkhttp://www.cosdna.com/chs/, dated—Oct. 26, 2018, pp. 1-10. [cited by applicant]
Mitsubishi-Kagaku Foods Corporation; Anonymous: Ryoto Sugar Ester (Food Grade), Internet Citation, XP002557521, Retrieved from the internet: URL: http://web.archive.org/web20080524191629/http://www.mfc.co.jp/english/sei… [cited by applicant]
Miyamoto et al. Skin Res Technology , “Development of a Digital Imaging System for Objective Measurement of Hyperpigmented Spots on the Face;” Skin Res Technology 2002; 8:227-35. [cited by applicant]
Niacinamide—Mechanisms of Action and Its Topical Use in Dermatology, Skin Pharmacol Physiol 2014, Jun. 27, 2014, pp. 311-315. [cited by applicant]
The use of gene arrays and corresponding connectivity mapping (cMap) to identify novel anti-ageing ingredients, International Journal of Cosmetic Science (2015), vol. 37 issue S1, p. 9-14. [cited by applicant]
Unpublished U.S. Appl. No. 17/549,989, filed Dec. 14, 2021, to Matthew Clair Ehrman et al. [cited by applicant]
Unpublished U.S. Appl. No. 18/074,577, filed Dec. 5, 2022 to Tomohiro NMN Hakozaki et al. [cited by applicant]
Vermeire et al., “Sucrose Laurate Gels as a Percutaneous Delivery System for Oestradiol in Rabbits”, Journal Of Pharmacy and Pharmacology, vol. 48, 1996, pp. 463-467. [cited by applicant]
“Lubrizol” Retrieved from https://www.lubrizol.com/−/media/Lubrizol/Personal-Care/Documents/Technical-Papers-and-Posters/MakeltSimple_Poster_DEC2012.pdf, Dec. 2012, 1 page. [cited by applicant]
“Stearyl Alcohol”, Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Stearyl-Alcohol, Aug. 10, 2020, 1 page. [cited by applicant]